Auour Investments’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Auour Investments’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$384K	Buy	+2,425	New	+$328K	0.11%	69

Other funds holding XBI

Main Street Research Lakeville, Connecticut $2.12B AUM 67.44% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $188M AUM

AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return

Whittier Trust South Pasadena, California $10.2B AUM 33.39% 1-Year Est. Return

Annex Advisory Services Brookfield, Wisconsin $5.86B AUM 21.83% 1-Year Est. Return

Weatherly Asset Management Del Mar, California $1.4B AUM 36.32% 1-Year Est. Return

Royal Fund Management Lady Lake, Florida $1.2B AUM 32.21% 1-Year Est. Return

New Harbor Financial Group Worcester, Massachusetts $633M AUM 37.53% 1-Year Est. Return

Riggs Asset Management Dallas, Pennsylvania $560M AUM 64.94% 1-Year Est. Return

Auour Investments's XBI Position: Q2 2026 in Review

Auour Investments opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q2 2026: 2,425 shares worth $384K. The stake represents 0.11% of the portfolio and ranks #69 among its holdings.

393 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Auour Investments held 2,425 shares of State Street SPDR S&P Biotech ETF worth $384K as of Q2 2026.
State Street SPDR S&P Biotech ETF was a new Auour Investments position in Q2 2026.
State Street SPDR S&P Biotech ETF made up 0.11% of Auour Investments's portfolio in Q2 2026, its #69 holding.
393 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Auour Investments's 13F filing for Q2 2026, filed 21 Jul 2026.